Adipotide (10 mg Vial) Dosage Protocol
Quickstart Highlights
Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro‑apoptotic sequence to destroy those vessels[1][2], resulting in targeted fat mass reduction as fat cells lose their blood supply[8]. Preclinical studies showed notable weight loss in obese rodents and primates[1][9]; however, clinical development was discontinued after a Phase 1 trial due to safety concerns[3][4]. This educational protocol presents a cautious once‑daily subcutaneous titration approach with careful dose escalation.
- Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration.
- Starting dose: 250 mcg once daily; gradual escalation by 250 mcg every 2 weeks as tolerated.
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[5].
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 units (0.08 mL) |
| Weeks 3–4 | 500 mcg | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) and starts at a conservative dose with gradual escalation to mitigate potential renal side effects observed at higher doses in preclinical studies[1][2]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[5].
Supplies Needed
Plan based on an 8–week cautious titration protocol with once‑daily administration.
-
Peptide Vials (Adipotide, 10 mg each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 10 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Targeted reduction of fat mass via vascular targeting in adipose tissue[2][8].
- Schedule: Daily subcutaneous injections for 4–8 weeks (cautious approach due to limited human data)[3][9].
- Dose Range: 250–1000 mcg daily with gradual titration every 2 weeks.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Dosing Protocol
Suggested daily titration approach.
- Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated[3][9].
- Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated).
- Frequency: Once per day (subcutaneous).
- Cycle Length: 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
- Timing: Any consistent time; rotate injection sites systematically.
Storage Instructions
Proper storage preserves peptide quality.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle[6][7].
- Document daily dose and site rotation to maintain consistency.
- Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher doses[3][4]. This protocol is for educational purposes only.
How This Works
Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium[2][8]. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized[1][2]. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment[1][9]. A first‑in‑human Phase 1 trial was initiated in obese cancer patients[3], but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher doses[4].
Potential Benefits & Side Effects
Observations from preclinical literature and limited human data.
- Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)[1][2][8][9].
- Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models[2].
- Safety concerns: Clinical development was discontinued due to safety issues[3][4]; reversible kidney toxicity was dose‑dependent in preclinical studies[1].
- Mild injection‑site reactions (redness, swelling) may occur with subcutaneous administration.
- Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
- Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6][7].
- Clean the vial stopper and skin with alcohol; allow to dry fully.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue)[6].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
- Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.
Recommended Source
We recommend Pure Lab Peptides for high‑purity Adipotide (10 mg).
Why Pure Lab Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Adipotide’s clinical development was discontinued due to safety concerns. This information is for research purposes only. Not for human consumption.
References
-
Science Translational Medicine (PubMed)
— A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys -
MD Anderson Cancer Center
— Obese Monkeys Lose Weight on Drug that Attacks Blood Supply of Fat Cells -
Arrowhead Pharmaceuticals News
— Dosing of First Patient with Anti-Obesity Treatment Adipotide in a Phase 1 Clinical Trial -
Cardiovascular Diabetology (PMC)
— Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT) -
Bachem Technical Note
— Care and Handling of Peptides -
BC Open Textbook Project
— 7.3 Intradermal and Subcutaneous Injections – Clinical Procedures for Safer Patient Care -
Immunize.org (IAC)
— Ask the Experts: Administering Vaccines – General Issues (no aspiration guidance) -
Los Angeles Times
— Cancer treatment shows promise for rapid weight loss -
ScienceDaily
— Obese monkeys lose weight on drug that attacks blood supply of fat cells -
CDC
— Vaccine administration: subcutaneous route guidance -
CDC (Subcut Injection PDF)
— Technique diagram and site guidance for subcutaneous injections -
NCBI Bookshelf
— Best practices for injection (asepsis, preparation, and administration) -
Subcutaneous Drug Injection Review (PMC)
— Pharmacologic considerations of the subcutaneous route -
Pure Lab Peptides
— Adipotide (10 mg) product page (quality and batch documentation)